Responses
Regular and young investigator award abstracts
Clinical trials in progress
349 Early safety and efficacy of a phase 1/2 open-label, multi-center trial of SNS-301 added to pembrolizumab in patients with advanced squamous cell carcinoma of the head and neck (SCCHN)
Compose a Response to This Article
Other responses
No responses have been published for this article.